Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307-Reference-Cited by-同舟云学术

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307

Published:2018-03-25 Issue:4 Volume:59 Page:866-876
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Krauss Gregory L.¹,Perucca Emilio²³,Kwan Patrick⁴⁵,Ben-Menachem Elinor⁶,Wang Xue-Feng⁷,Shih Jerry J.⁸,Patten Anna⁹,Yang Haichen¹⁰,Williams Betsy¹¹,Laurenza Antonio¹¹

Affiliation:

1. Department of Neurology; Johns Hopkins University; Baltimore MD USA

2. IRCCS Mondino Foundation; Pavia Italy

3. Department of Internal Medicine and Therapeutics; University of Pavia; Pavia Italy

4. Royal Melbourne Hospital; University of Melbourne; Parkville Vic. Australia

5. Prince of Wales Hospital; The Chinese University of Hong Kong; Hong Kong China

6. Sahlgrenska Academy; Gothenburg Sweden

7. Chongqing Key Laboratory of Neurology; First Affiliated Hospital of Chongqing Medical University; Chongqing China

8. Department of Neurosciences; UCSD School of Medicine; La Jolla CA USA

9. Department of Biostatistics; Eisai Ltd.; Hatfield UK

10. Former Employee of Eisai Inc.; Woodcliff Lake NJ USA

11. Eisai Neurology Business Group; Eisai Inc.; Woodcliff Lake NJ USA

Funder

Eisai

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.14044/fullpdf

Reference15 articles.

1. European Medicines Agency (EMA) Fycompa ® Annex I: Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf

2. Food and Drug Administration (FDA) Fycompa ® Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202834s012,208277s001lbl.pdf

3. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures;Krauss;Neurology,2012

4. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304;French;Neurology,2012

5. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305;French;Epilepsia,2013

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy;Epilepsy Research;2024-02

2. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma;BMC Cancer;2024-01-26

3. Long‐term efficacy and safety of adjunctive perampanel in patients from the Asia‐Pacific region with refractory focal‐onset seizures in Study 335 open‐label extension;Epilepsia Open;2024-01-06

4. Perampanel as only add-on epilepsy treatment in elderly: A subgroup analysis of real-world data from retrospective, multicenter, observational study;Journal of the Neurological Sciences;2023-12

5. Perampanel-induced erectile dysfunction;Neurological Sciences;2023-11-30